Melanotan Injections Linked to Rapid Development of Atypical Moles

Melanotan is a synthetic analogue of alpha-MSH (alpha melanocyte stimulating hormone), a natural peptide that stimulates melanogenesis (the production of melanin pigment). It is often marketed online and in tanning salons as a 'tanning jab' for rapid skin darkening. Despite its cosmetic appeal, the long-term safety profile of Melanotan, particularly its potential impact on skin health and the development of atypical melanocytic naevi (moles with irregular features that can be precursors to skin cancer), remains poorly understood. This study addresses the potential dermatological risks associated with Melanotan use, specifically the rapid onset of atypical moles.

Following the administration of two Melanotan injections, the patient rapidly developed multiple new onset atypical naevi (moles with irregular features, potentially precancerous). These new lesions appeared within a remarkably short timeframe of just one week post-injection. Dermoscopy confirmed the atypical characteristics of these newly formed moles. The most critical finding was the rapid emergence of multiple new atypical naevi within one week of receiving Melanotan, directly linking the synthetic peptide to concerning dermatological changes. This observation highlights a direct temporal association between Melanotan use and the development of potentially dysplastic skin changes, suggesting a significant and concerning dermatological response.